Vivazome
Sydney, Australia· Est.
Australian exosome biotech targeting TBI, stroke and neurodegeneration with GMP‑scale EV therapeutics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australian exosome biotech targeting TBI, stroke and neurodegeneration with GMP‑scale EV therapeutics.
NeurologyNeurodegeneration
Technology Platform
Proprietary exosome (extracellular vesicle) platform that engineers cell sources, loads therapeutic cargo, and uses a scalable GMP manufacturing process to produce targeted, low‑immunogenic biologics.
Opportunities
Large unmet need in neuro‑inflammatory disorders and a rapidly expanding exosome therapeutics market provide a clear path for premium valuation and strategic partnerships.
Risk Factors
Regulatory uncertainty for EV products and technical challenges of scaling GMP‑grade exosome manufacturing could delay clinical progress and increase capital requirements.
Competitive Landscape
Key competitors include Codiak BioSciences, Exo Therapeutics and Axiom, all developing EV‑based therapeutics; VivaZome differentiates through its focus on neurological indications and a proprietary, integrated manufacturing platform.